Reverse Transcriptase Polymerase Chain Reaction: Clinical Trials

21 trials of Reverse Transcriptase Polymerase Chain Reaction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 8 terminated. 21 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 221Completed 13, Terminated 8
Phase 15Completed 4, Terminated 1

Follow Reverse Transcriptase Polymerase Chain Reaction: new trials by email Literature Review of Reverse Transcriptase Polymerase Chain Reaction trials Research Report on Reverse Transcriptase Polymerase Chain Reaction

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Phase 2CompletedBarbara Ann Karmanos Cancer Institute182011-01-012018-09-18
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
letrozole, panobinostat, RNA analysis - Breast Cancer
Phase 1 / Phase 2CompletedAlliance for Clinical Trials in Oncology282010-09-012017-06-27
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
azacitidine, lenalidomide, dexamethasone - Refractory Multiple Myeloma
Phase 1 / Phase 2CompletedCase Comprehensive Cancer Center452010-06-012020-11-16
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction - Leukemia
Phase 2TerminatedCity of Hope Medical Center162008-04-012014-09-09
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
cetuximab, carboplatin, cisplatin - Head and Neck Cancer
Phase 2TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC472008-02-012018-07-09
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction - Brain and Central Nervous System Tumors
Phase 2CompletedMemorial Sloan Kettering Cancer Center472007-06-012016-02-29
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx
carboplatin, cisplatin, docetaxel - Head and Neck Cancer
Phase 1 / Phase 2CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC72007-05-012018-07-09
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
trastuzumab, cyclophosphamide, doxorubicin hydrochloride - Breast Cancer, Cardiac Toxicity
Phase 2CompletedMayo Clinic1222007-03-162022-08-05
Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer
capecitabine, oxaliplatin, gene expression analysis - Esophageal Cancer
Phase 2CompletedRoswell Park Cancer Institute412006-11-012013-11-25
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
everolimus, antiangiogenesis therapy, biopsy - Colorectal Cancer
Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins12006-10-012014-10-08
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
oxaliplatin, pemetrexed disodium, questionnaire administration - Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Phase 2CompletedUniversity of Southern California472006-06-012014-03-10
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide - Breast Cancer
Phase 2CompletedUniversity of Nebraska172006-05-012023-09-29
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
nelfinavir mesylate, biopsy, laboratory biomarker analysis - Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 1 / Phase 2TerminatedCity of Hope Medical Center292006-03-012015-04-01
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
celecoxib, recombinant interferon alfa-2b, polymerase chain reaction - Renal Cell Cancer, Stage IV Renal Cell Cancer
Phase 2CompletedCase Comprehensive Cancer Center172006-03-012012-08-07
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction - Leukemia
Phase 2TerminatedOHSU Knight Cancer Institute42005-10-012011-09-02
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
cetuximab, capecitabine, gene expression analysis - Colorectal Cancer
Phase 2TerminatedCity of Hope Medical Center132005-08-012014-08-28
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
bortezomib, pemetrexed disodium, gene expression analysis - Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Phase 1 / Phase 2CompletedUniversity of California, Davis272005-03-012018-10-31
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
Docetaxel, Floxuridine, Leucovorin - Esophageal Cancer
Phase 2CompletedUniversity of Miami292004-10-012017-02-07
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
filgrastim, capecitabine, celecoxib - Breast Cancer
Phase 2TerminatedUniversity of Nebraska32004-04-152023-09-13
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
aldesleukin, idiotype-pulsed autologous dendritic cell vaccine APC8020, recombinant interferon gamma - Multiple Myeloma and Plasma Cell Neoplasm
Phase 2CompletedMayo Clinic152001-08-012011-05-16

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Breast Neoplasms (4)  ·  Adenocarcinoma Of Esophagus (2)  ·  Breast Neoplasms, Male (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colonic Neoplasms (2)  ·  Colorectal Neoplasms (2)  ·  Esophageal Neoplasms (2)  ·  Head and Neck Neoplasms (2)  ·  Leukemia (2)  ·  Lung Neoplasms (2)  ·  Multiple Myeloma (2)  ·  Prostatic Neoplasms (2)  ·  Rectal Neoplasms (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Astrocytoma (1)

Sponsors

City of Hope Medical Center (4)  ·  Case Comprehensive Cancer Center (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Mayo Clinic (2)  ·  University of Nebraska (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  OHSU Knight Cancer Institute (1)  ·  Roswell Park Cancer Institute (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  University of California, Davis (1)  ·  University of Miami (1)  ·  University of Southern California (1)

Countries

United States (17)  ·  Belgium (2)

Top investigators

Ahmad Awada, MD, PhD (1)  ·  Angela Davies, MD (1)  ·  Antonio Omuro, MD (1)  ·  Bach Ardalan, MD (1)  ·  Brian Rini (1)  ·  Donald W. Northfeld, MD (1)  ·  Edith A. Perez, MD (1)  ·  Ehsan Malek, MD (1)  ·  Elisabeth Heath (1)  ·  Elizabeth C Reed, MD (1)  ·  Elizabeth C. Reed, MD (1)  ·  Frederic Reu (1)  ·  Jacek Pinski (1)  ·  James N. Ingle, MD (1)  ·  Jan B. Vermorken, MD, PhD (1)

Results publications

PMID 18090584, PMID 21258083, PMID 22989664, PMID 23243055, PMID 24099865, PMID 26774555, PMID 35135810

NIH funding

P30CA033572 (3), P30CA015083 (2), P30CA036727 (2), P30CA008748 (1)